<div id="readability-page-1"><p>Stephens Inc. AR reduced its stake in shares of  Novo Nordisk A/S (NYSE:NVO - Free Report) by 83.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor  owned 25,128 shares of the company's stock after selling 125,281 shares during the quarter. Stephens Inc. AR's holdings in Novo Nordisk A/S were worth $1,394,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Novo Nordisk A/S</strong> alerts:</span></p></div><ul><li>Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns</li></ul><p>Several other hedge funds have also bought and sold shares of the stock. Lockheed Martin Investment Management Co. increased its position in shares of  Novo Nordisk A/S by 179.4% during the second quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company's stock valued at $2,999,000 after acquiring an additional 27,900 shares during the last quarter.  Martin Capital Partners LLC boosted its position in shares of  Novo Nordisk A/S by 53.8% during the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company's stock worth $6,524,000 after purchasing an additional 41,129 shares during the period.  Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in  Novo Nordisk A/S in the 3rd quarter valued at approximately $1,294,000.  Unified Investment Management purchased a new stake in  Novo Nordisk A/S in the second quarter valued at approximately $692,000.  Finally, Guild Investment Management Inc. lifted its stake in  Novo Nordisk A/S by 20.7% during the second quarter. Guild Investment Management Inc. now owns 36,995 shares of the company's stock worth $2,553,000 after purchasing an additional 6,345 shares in the last quarter. Hedge funds and other institutional investors own  11.54% of the company's stock. </p><h2>Novo Nordisk A/S Price Performance</h2><p>Novo Nordisk A/S stock opened at $62.32 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The company has a fifty day simple moving average of $50.85 and a 200-day simple moving average of $54.97. The stock has a market cap of $278.26 billion, a P/E ratio of 18.12 and a beta of 0.66. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80. </p><ul><li>This ETF Is Proof That the Healthcare Rebound Is Real</li></ul><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.77 by $0.25. The company had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. Equities analysts expect that  Novo Nordisk A/S will post 3.84 EPS for the current fiscal year. </p><h2>Key Headlines Impacting Novo Nordisk A/S</h2><p>Here are the key news stories impacting Novo Nordisk A/S this week:</p><ul>   <li><span>Positive Sentiment: </span>Early U.S. launch showed encouraging demand — oral Wegovy recorded 3,071 prescriptions in the first four days after launch, a datapoint traders flagged as a strong initial uptake. Read More.</li>    <li><span>Positive Sentiment: </span>Analyst notes described the rollout as a “solid start,” supporting upside expectations while emphasizing the need for more data to gauge sustained demand. Read More.</li>    <li><span>Positive Sentiment: </span>U.K. regulator approved a higher Wegovy dose (up to 7.2 mg weekly), expanding label flexibility and the addressable market for higher‑intensity treatment. Read More.</li>    <li><span>Neutral Sentiment: </span>Some analysts caution early prescription figures may not fully reflect long‑term demand or uptake dynamics; UBS warned initial data can be misleading even while it lifted its price target. Read More.</li>    <li><span>Neutral Sentiment: </span>High trading volume and elevated market attention increase short‑term volatility as investors parse launch metrics, regulation and competitor actions. Read More.</li>    <li><span>Negative Sentiment: </span>Legal risk: a compounding pharmacy has sued Novo (and Eli Lilly) over GLP‑1 access, alleging antitrust issues — a development prompting near‑term share pressure and regulatory/legal expense risk. Read More.</li>    <li><span>Negative Sentiment: </span>Valuation concerns persist: commentary argues Novo’s current valuation may not fully justify bullishness if growth or pricing faces headwinds, a viewpoint that can temper upside. Read More.</li> </ul><h2>Wall Street Analyst Weigh In</h2><ul><li>FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026</li></ul><p>A number of equities research analysts have recently weighed in on the company. CICC Research started coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an &#34;outperform&#34; rating and a $73.50 price objective for the company. Morgan Stanley  restated an &#34;underweight&#34; rating and set a $42.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Jefferies Financial Group assumed coverage on shares of Novo Nordisk A/S in a research note on Monday, October 27th. They set an &#34;underperform&#34; rating on the stock. Zacks Research raised shares of Novo Nordisk A/S from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Friday, January 9th. Finally, Hsbc Global Res cut shares of Novo Nordisk A/S from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, November 24th. One analyst  has rated the stock with a Strong Buy rating, seven have issued  a Buy rating, twelve have given a Hold rating and three have issued  a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and an average price target of $56.21.</p><p><b>View Our Latest Stock Report on NVO</b></p><h2>Novo Nordisk A/S Profile</h2> (Free Report)<p>Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.  </p><p>The company's core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.</p><h2>See Also</h2><ul><li>Five stocks we like better than Novo Nordisk A/S</li><li>Wall Street Alert: Buy AES</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>Do not delete, read immediately</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>URGENT: Trump Just Triggered AI’s Biggest Disruption Yet</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Stephens Inc. AR has significantly reduced its stake in Novo Nordisk A/S by 83.3% in Q3, now holding 25,128 shares valued at $1.39 million. Other institutional investors have also adjusted their positions, with Lockheed Martin Investment Management increasing its stake by 179.4%. Novo Nordisk's stock performance shows a market cap of $278.26 billion and a P/E ratio of 18.12. The company reported earnings of $1.02 per share, exceeding estimates, while analysts remain cautious about long-term demand for its products amid legal and valuation concerns.</p>

Stephens Inc. AR Lowers Holdings in Novo Nordisk A/S $NVO